Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Satavaptan
SR121463B · 8 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| Satavaptan | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Satavaptan | DRUG | oral administration once daily |
| placebo | DRUG | oral administration once daily |
| SR121463B | DRUG | - |
| satavaptan (SR121463B) | DRUG | - |
Inclusion Criteria: * Participants with cirrhosis of the liver * Participants with clinically evident ascites primarily managed by diet and/or diuretics * Stable treatment of ascites for at least the previous 2 weeks without paracentesis * Participants having undergone no more than one therapeutic ...
SR121463B is an investigational small molecule being studied for the treatment of Inappropriate ADH Syndrome, a condition also known as Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH), which causes hyponatremia, and for Congestive Heart Failure. It is being developed by Sanofi and is in Phase 3 clinical development.
SR121463B is being developed by Sanofi, a global pharmaceutical company traded on the stock exchange under the ticker symbol SNY. The drug is currently in Phase 3 clinical trials for Inappropriate ADH Syndrome and Congestive Heart Failure.
SR121463B is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. Three Phase 3 trials have been completed, with a total enrollment of 150 patients across studies.
SR121463B has been studied in three completed Phase 3 trials. NCT00264914 and NCT00264927 evaluated the drug in patients with Inappropriate ADH Syndrome and hyponatremia, enrolling 57 and 77 patients respectively. NCT00274326, titled DILIPO, studied the drug in 150 patients with Congestive Heart Failure.
No, SR121463B is not the same as tolvaptan. SR121463B is a distinct investigational small molecule developed by Sanofi for Inappropriate ADH Syndrome and Congestive Heart Failure. It is currently in Phase 3 clinical development and has not been approved for any use.